Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
121.52
-4.33 (-3.44%)
Nov 17, 2026, 4:00 PM EST - Market closed
Kymera Therapeutics Revenue
Kymera Therapeutics had revenue of $102.24M in the twelve months ending September 30, 2026, up 133.77% year-over-year. In the year 2025, Kymera Therapeutics had annual revenue of $39.21M, down -16.70%. That makes Kymera Therapeutics the 22,543rd largest company in the world by revenue and 3,272nd in the United States.
Revenue (ttm)
$102.24M
Revenue Growth
+133.77%
P/S Ratio
101.48
Revenue / Employee
$358,719
Employees
285
Market Cap
10.37B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 39.21M | -7.86M | -16.70% |
| Dec 31, 2024 | 47.07M | -31.52M | -40.11% |
| Dec 31, 2023 | 78.59M | 31.77M | 67.84% |
| Dec 31, 2022 | 46.83M | -26.01M | -35.71% |
| Dec 31, 2021 | 72.83M | 38.80M | 114.00% |
| Dec 31, 2020 | 34.03M | 31.10M | 1,059.99% |
| Dec 31, 2019 | 2.93M | - | - |
| Dec 31, 2018 | 2.93M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BioMarin Pharmaceutical | 3.66B |
| Halozyme Therapeutics | 1.80B |
| Madrigal Pharmaceuticals | 1.43B |
| Bio-Techne | 1.23B |
| TG Therapeutics | 897.76M |
| Krystal Biotech | 470.03M |
| Praxis Precision Medicines | 7.46M |
KYMR News
- 15 days ago - Kymera Therapeutics price target raised to $170 from $139 at Barclays - TheFly
- 18 days ago - Kymera Therapeutics price target raised to $150 from $146 at Morgan Stanley - TheFly
- 19 days ago - Kymera Therapeutics price target raised to $144 from $140 at Raymond James - TheFly
- 19 days ago - Kymera Therapeutics Earnings Call Transcript: Q3 2026 - Transcripts
- 19 days ago - Kymera Therapeutics Earnings release: Q3 2026 - Filings
- 19 days ago - Kymera Therapeutics Quarterly report: Q3 2026 - Filings
- 19 days ago - Kymera Therapeutics Slides: Q3 2026 - Filings
- 19 days ago - Kymera Therapeutics Slides: Company presentation - Filings